Three strategies for managing loss of exclusivity successfully
pharmaphorum
FEBRUARY 18, 2021
Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. 6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog.
52 
Let's personalize your content